Johannes Betge

Johannes Betge

Auto-generated profile, based on publicly available information

Johannes Betge

Junior Clinical Cooperation Unit Translational Gastrointestinal Oncology and Preclinical Models, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Seminars in Cancer Biology
Verified
Journal Article
Open access
TZTianzuo Zhan
Tianzuo Zhan
NRNiklas Rindtorff
Niklas Rindtorff
JBJohannes Betge
Johannes Betge
MEMatthias P. Ebert
Matthias P. Ebert
MBMichael Boutros
Michael Boutros
CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system, CRISPR/Cas9 and modified versions have found a widespread use to engineer genomes and to activate or to repress the expression of genes. As such, CRISPR/Cas9 promises to accelerate cancer research by providing an efficient technology to dissect mechanisms of tumorigenesis, identify targets for drug development, and possibly arm cells for cell-based therapies. Here, we review current applications of the CRISPR/Cas9 technology for cancer research and therapy. We describe novel Cas9 variants and how they are used in functional genomics to discover novel cancer-specific vulnerabilities. Furthermore, we highlight the impact of CRISPR/Cas9 in generating organoid and mouse models of cancer. Finally, we provide an overview of the first clinical trials that apply CRISPR/Cas9 as a therapeutic approach against cancer.

12 July 2011 in Cancer
Verified
Journal Article
Closed access
PDF file
JBJohannes Betge
Johannes Betge
MPMarion J. Pollheimer
Marion J. Pollheimer
RLRichard A. Lindtner
Richard A. Lindtner
PKPeter Kornprat
Peter Kornprat
ASAndrea Schlemmer
Andrea Schlemmer
CLCord Langner
Cord Langner

16 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
TZTianzuo Zhan
Tianzuo Zhan
GAGiulia Ambrosi
Giulia Ambrosi
AWAnna Maxi Wandmacher
Anna Maxi Wandmacher
BRBenedikt Rauscher
Benedikt Rauscher
JBJohannes Betge
Johannes Betge
MBMichael Boutros
Michael Boutros
In colorectal cancer (CRC), aberrant Wnt signalling is essential for tumorigenesis and maintenance of cancer stem cells. However, how other oncogenic pathways converge on Wnt signalling to modulate stem cell homeostasis in CRC currently remains poorly understood. Using large-scale compound screens in CRC, we identify MEK1/2 inhibitors as potent activators of Wnt/β-catenin signalling. Targeting MEK increases Wnt activity in different CRC cell lines and murine intestine in vivo. Truncating mutations of APC generated by CRISPR/Cas9 strongly synergize with MEK inhibitors in enhancing Wnt responses in isogenic CRC models. Mechanistically, we demonstrate that MEK inhibition induces a rapid downregulation of AXIN1. Using patient-derived CRC organoids, we show that MEK inhibition leads to increased Wnt activity, elevated LGR5 levels and enrichment of gene signatures associated with stemness and cancer relapse. Our study demonstrates that clinically used MEK inhibitors inadvertently induce stem cell plasticity, revealing an unknown side effect of RAS pathway inhibition.

14 June 2016 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
JBJohannes Betge
Johannes Betge
NSNora I. Schneider
Nora I. Schneider
LHLars Harbaum
Lars Harbaum
MPMarion J. Pollheimer
Marion J. Pollheimer
RLRichard A. Lindtner
Richard A. Lindtner
CLCord Langner
Cord Langner
Mucin glycoprotein expression can be altered during the carcinogenic process. The impact on the prognosis of patients with colorectal cancer (CRC) is controversial. We analyzed tumors from 381 patients for MUC1, MUC2, MUC5AC, and MUC6 expression by immunohistochemical staining, using tissue microarrays. Progression-free and cancer-specific survival were determined using the Kaplan-Meier method. Expression of intestinal mucin MUC2 was lost in 85 (23 %) CRCs, and patients with MUC6-negative tumors showed shorter progression-free survival (PFS, p = 0.043). Gastric mucins MUC5AC and MUC6 showed high (>50 %) aberrant expression in 28 (8 %) and 9 (2 %) cases, respectively. High expression of MUC5AC was associated with longer PFS (p = 0.055). High expression of MUC6 was associated with 100 % PFS (p = 0.024) and longer cancer-specific survival (CSS, p = 0.043). MUC1 was expressed in 238 (64 %) tumors and had no impact on outcome. When analysis was restricted to stages II and III, loss of MUC2 was associated with adverse outcome. Overexpression of both MUC5AC and MUC6 significantly predicted favorable PFS and CSS. In conclusion, loss of MUC2 expression proved to be a predictor of adverse outcome, while the gain of aberrant expression of MUC5AC and particularly of MUC6 was associated with favorable outcome in CRC, notably in intermediate stages II and III.

15 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
YQYuquan Qian
Yuquan Qian
Jimmy Daza BarraganJimmy Daza Barragan
Jimmy Daza Barragan
TITimo Itzel
Timo Itzel
JBJohannes Betge
Johannes Betge
TZTianzuo Zhan
Tianzuo Zhan
ATAndreas Teufel
Andreas Teufel
Current staging systems of cancer are mainly based on the anatomical extent of disease. They need refinement by biological parameters to improve stratification of patients for tumor therapy or surveillance strategies. Thanks to developments in genomic, transcriptomic, and big-data technologies, we are now able to explore molecular characteristics of tumors in detail and determine their clinical relevance. This has led to numerous prognostic and predictive gene expression signatures that have the potential to establish a classification of tumor subgroups by biological determinants. However, only a few gene signatures have reached the stage of clinical implementation so far. In this review article, we summarize the current status, and present and future challenges of prognostic gene signatures in three relevant cancer entities: breast cancer, colorectal cancer, and hepatocellular carcinoma.

6 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJohannes Betge
Johannes Betge
NRNiklas Rindtorff
Niklas Rindtorff
JSJan Sauer
Jan Sauer
BRBenedikt Rauscher
Benedikt Rauscher
CDClara Dingert
Clara Dingert
MBMichael Boutros
Michael Boutros
Patient-derived organoids resemble the biology of tissues and tumors, enabling ex vivo modeling of human diseases. They have heterogeneous morphologies with unclear biological causes and relationship to treatment response. Here, we use high-throughput, image-based profiling to quantify phenotypes of over 5 million individual colorectal cancer organoids after treatment with >500 small molecules. Integration of data using multi-omics modeling identifies axes of morphological variation across organoids: Organoid size is linked to IGF1 receptor signaling, and cystic vs. solid organoid architecture is associated with LGR5 + stemness. Treatment-induced organoid morphology reflects organoid viability, drug mechanism of action, and is biologically interpretable. Inhibition of MEK leads to cystic reorganization of organoids and increases expression ofLGR5, while inhibition of mTOR induces IGF1 receptor signaling. In conclusion, we identify shared axes of variation for colorectal cancer organoid morphology, their underlying biological mechanisms, and pharmacological interventions with the ability to move organoids along them.